Merck & Co., Inc. (NYSE:MRK)

A6++

This one has become too big and risky, especially if Januvia goes down due to pancreatitis concerns.

Merck sells it's drugs internationally. Most importantly to developing nations.

Dow 30 stock bouncing on 200 DMA

Dowjones in maximums.

#4 High Yield DOD

Januvia and Janumet are poised to explode with the diabetes market. Suvorexant and odanacatib both look good, and keeping all its divisions together (rather than spinning them off a la Abbott and Pfizer) should allow Merck to capitalize on growth segments. This company's done well in compensating for Singulair's loss.

This company will really conquer the S&P 500 performance. This weeks for sure.

brought in more than $3.2billion 2011 animal health one yr growth +39.16% income growth + 628.40% Sales growth +450%

Has been on a little romp and should continue to impress us with a decent dividend.

pharma, older population

Dog

Short term pain with patent expirations, but long term gain with great pipeline. In the interim, limited downside with good dividend.

The new Healthcare Legislation ratified by "The Supremes" will increase the demand for Healthcare by the population of the United States. All Healthcare providers will benefit -- Less, of course, the reality of Price Controls.

Still, however a Net Positive and gain for BIG Pharma including Merck.

WHOVenturePartners, LLC
05 July 2012

New product in for FDA approval. Poised for a run.

Patent expiration and generic competition will further compress earnings over the next year.

the street

Here's the video pitch:

http://www.fool.com/investing/general/2012/02/02/the-5-year-outlook-for-this-dow-stock-merck.aspx

Is there really any words to say about this giant pharma ? I just bought some nice pile of stocks today , for the dividend , the defensivness and long term global growth prospects. If Merck is going down then be sure that the rest of the world is financially doomed also. One of my favorite pharma plays at a bargin price.